Fructose-1,6-bisphosphatase as a therapeutic target for type 2 diabetes

Overproduction of glucose by gluconeogenesis is a primary determinant of hyperglycemia in patients with type 2 diabetes. Current drugs neither inhibit glucose production directly nor provide adequate glycemic control. As reviewed herein, the recent discovery and characterization of potent and selective inhibitors of fructose-1,6-bisphosphatase (FBPase) has provided new insights into the therapeutic utility of gluconeogenesis inhibitors and the potential of FBPase inhibitors as a new class of antidiabetic drugs.

Section editors:Ramakanth Sarabu and Jefferson W. Tilley – Roche Research Center, Nutley, NJ 07110, USA